CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Histologically confirmed diffuse or mediastinal large B-cell lymphoma with advanced/metastatic, incurable, relapsed or refractory disease
  • ✓Bidimensionally measurable disease by CT/MRI/physical exam (lymph nodes ≥1.5 cm × 1.5 cm or non-nodal regions ≥1 cm × 1 cm)
  • ✓1-2 prior chemotherapy regimens containing doxorubicin (stem cell transplant counts as one regimen)
  • ✓ECOG performance status 0-1
Key exclusion· 9
  • ✕Known brain metastases
  • ✕Prior therapy with antiangiogenic agents or multitargeted tyrosine kinase inhibitors (bevacizumab, sorafenib, pazopanib, thalidomide, etc.)
  • ✕Inability to take oral medication or absorb sunitinib due to GI tract disease, prior surgical procedures affecting absorption, or active peptic ulcer disease
  • ✕Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past 28 days

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00392496
NCT00392496Phase 2Completed
CompareCT.gov

A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)·interventional·Posted Oct 26, 2006·Updated May 15, 2014

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Adult Diffuse Large Cell Lymphoma and 2 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory diffuse or mediastinal large B-cell lymphoma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2006
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.7 years ago

Interventions

sunitinib malatedrug

Given orally